Mostrar el registro sencillo del ítem

dc.contributor.author
Lopez, Beatriz  
dc.contributor.author
Siqueira De Oliveira, Rosangela  
dc.contributor.author
Pinhata, Juliana M. W.  
dc.contributor.author
Chimara, Erica  
dc.contributor.author
Pacheco Ascencio, Edson  
dc.contributor.author
Puyén Guerra, Zully M.  
dc.contributor.author
Wainmayer, Ingrid  
dc.contributor.author
Símboli, Norberto Fabián  
dc.contributor.author
Del Granado, Mirtha  
dc.contributor.author
Palomino, Juan Carlos  
dc.contributor.author
Ritacco, Gloria Viviana  
dc.contributor.author
Martin, Anandi  
dc.date.available
2020-11-11T19:12:54Z  
dc.date.issued
2019-02  
dc.identifier.citation
Lopez, Beatriz; Siqueira De Oliveira, Rosangela; Pinhata, Juliana M. W.; Chimara, Erica; Pacheco Ascencio, Edson; et al.; Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region; Oxford University Press; Journal of Antimicrobial Chemotherapy; 74; 2; 2-2019; 373-379  
dc.identifier.issn
0305-7453  
dc.identifier.uri
http://hdl.handle.net/11336/118177  
dc.description.abstract
Objectives To describe the distributions of bedaquiline and linezolid MIC values for the Mycobacterium tuberculosis WT population and to define the corresponding epidemiological cut-offs (ECOFFs) in three Latin American countries. Methods MICs of bedaquiline and linezolid were determined by the resazurin microtitre assay (REMA). In phase 1, interlaboratory reproducibility was assessed using a panel of 10 fully susceptible M. tuberculosis strains. Phase 2 involved MIC determination for 248 clinical isolates from Argentina (n = 58), Brazil (n = 100) and Peru (n = 90) from patients who were treatment-naive for bedaquiline and linezolid. We then determined the ECOFFs for bedaquiline and linezolid by the eyeball method and the ECOFFinder statistical calculator. Results Phase 1: REMA MIC values in the three sites were either identical to each other or differed by one 2-fold dilution from the consensus value with the exception of a single value. Phase 2: The bedaquiline MIC range was 0.0039-0.25 mg/L for pan-susceptible and drug-resistant isolates combined. The linezolid MIC range was 0.062-0.5 mg/L for pan-susceptible isolates and 0.031-4 mg/L for drug-resistant isolates. ECOFFs were 0.125 mg/L for bedaquiline and 0.50 mg/L for linezolid. Conclusions REMA is reproducible and robust for the determination of bedaquiline and linezolid MIC distributions and ECOFF values when applied in laboratories of medium/low-resource countries. We suggest that WT MIC distributions for both drugs should be used as a monitoring tool to control the possible rapid emergence of resistance.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Oxford University Press  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
MICROBIAL DRUG SENSITIVITY ASSAY  
dc.subject
MINIMUM INHIBITORY CONCENTRATION  
dc.subject
MICROBIAL DRUG RESISTANCE  
dc.subject
ANTIMICROBIAL SUSCEPTIBILITY BREAKPOINT DETERMINATION  
dc.subject.classification
Biología Celular, Microbiología  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2020-11-11T12:31:04Z  
dc.journal.volume
74  
dc.journal.number
2  
dc.journal.pagination
373-379  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Oxford  
dc.description.fil
Fil: Lopez, Beatriz. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina  
dc.description.fil
Fil: Siqueira De Oliveira, Rosangela. Instituto Adolfo Lutz; Brasil  
dc.description.fil
Fil: Pinhata, Juliana M. W.. Instituto Adolfo Lutz; Brasil  
dc.description.fil
Fil: Chimara, Erica. Instituto Adolfo Lutz; Brasil  
dc.description.fil
Fil: Pacheco Ascencio, Edson. Instituto Nacional de Salud; Perú  
dc.description.fil
Fil: Puyén Guerra, Zully M.. Instituto Nacional de Salud; Perú  
dc.description.fil
Fil: Wainmayer, Ingrid. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina  
dc.description.fil
Fil: Símboli, Norberto Fabián. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina  
dc.description.fil
Fil: Del Granado, Mirtha. Pan American Health Organization; Estados Unidos  
dc.description.fil
Fil: Palomino, Juan Carlos. University of Ghent; Bélgica  
dc.description.fil
Fil: Ritacco, Gloria Viviana. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Martin, Anandi. Université Catholique de Louvain; Bélgica  
dc.journal.title
Journal of Antimicrobial Chemotherapy  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1093/jac/dky414  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/jac/article/74/2/373/5144701